Compare Stocks: QLGN, INM, SNOA, and LIAN

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
INM InMed Pharmaceuticals	$1.47 -2.0%	$1.58	$0.58 ▼ $2.56	$4.87M	0.95	2.76 million shs	257,037 shs
LIAN LianBio	$0.05 -16.6%	$0.11	$0.27 ▼ $4.99	$5.20M	0.23	1.04 million shs	13,100 shs
QLGN Qualigen Therapeutics	$0.66 -1.3%	$1.12	$1.61 ▼ $8.81	$1.12M	0.24	1.52 million shs	10,974 shs
SNOA Sonoma Pharmaceuticals	$1.10 -2.7%	$1.16	$0.85 ▼ $6.92	$5.27M	1.27	55,768 shs	26,412 shs

The 7 Hottest IPO Stories of 2026

MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
INM InMed Pharmaceuticals	0.00%	-14.04%	-5.77%	+105.74%	-41.67%
LIAN LianBio	-16.57%	-7.50%	-58.17%	-60.41%	-8.38%
QLGN Qualigen Therapeutics	-1.25%	-19.41%	-45.75%	-55.28%	-73.74%
SNOA Sonoma Pharmaceuticals	0.00%	-3.51%	-9.09%	-8.33%	-64.40%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
INM InMed Pharmaceuticals	$1.47 -2.0%	$1.58	$0.58 ▼ $2.56	$4.87M	0.95	2.76 million shs	257,037 shs
LIAN LianBio	$0.05 -16.6%	$0.11	$0.27 ▼ $4.99	$5.20M	0.23	1.04 million shs	13,100 shs
QLGN Qualigen Therapeutics	$0.66 -1.3%	$1.12	$1.61 ▼ $8.81	$1.12M	0.24	1.52 million shs	10,974 shs
SNOA Sonoma Pharmaceuticals	$1.10 -2.7%	$1.16	$0.85 ▼ $6.92	$5.27M	1.27	55,768 shs	26,412 shs

The 7 Hottest IPO Stories of 2026

MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
INM InMed Pharmaceuticals	0.00%	-14.04%	-5.77%	+105.74%	-41.67%
LIAN LianBio	-16.57%	-7.50%	-58.17%	-60.41%	-8.38%
QLGN Qualigen Therapeutics	-1.25%	-19.41%	-45.75%	-55.28%	-73.74%
SNOA Sonoma Pharmaceuticals	0.00%	-3.51%	-9.09%	-8.33%	-64.40%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
INM InMed Pharmaceuticals	1.00	Sell	N/A	N/A
LIAN LianBio	0.00	N/A	N/A	N/A
QLGN Qualigen Therapeutics	1.00	Sell	N/A	N/A
SNOA Sonoma Pharmaceuticals	1.00	Sell	N/A	N/A

Current Analyst Ratings Breakdown

Latest QLGN, INM, SNOA, and LIAN Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target	Details
7/24/2026	SNOA Sonoma Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)
6/24/2026	INM InMed Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)

(Data available from 8/2/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
INM InMed Pharmaceuticals	$4.94M	0.98	N/A	N/A	$6.71 per share	0.22
LIAN LianBio	N/A	N/A	N/A	N/A	$2.71 per share	N/A
QLGN Qualigen Therapeutics	N/A	N/A	N/A	N/A	($4.12) per share	N/A
SNOA Sonoma Pharmaceuticals	$19.53M	0.27	N/A	N/A	$0.65 per share	1.69

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
INM InMed Pharmaceuticals	-$8.16M	-$2.89	N/A	N/A	N/A	-132.87%	-80.85%	-68.11%	9/23/2026 (Estimated)
LIAN LianBio	-$110.29M	-$0.81	N/A	N/A	N/A	N/A	-33.17%	-30.19%	N/A
QLGN Qualigen Therapeutics	-$6.26M	-$7.50	N/A	N/A	N/A	N/A	N/A	-202.16%	N/A
SNOA Sonoma Pharmaceuticals	-$3.17M	-$1.89	N/A	N/A	N/A	-16.26%	-43.95%	-11.27%	8/6/2026 (Estimated)

Latest QLGN, INM, SNOA, and LIAN Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/6/2026	N/A	SNOA Sonoma Pharmaceuticals	-$0.30	N/A	N/A	N/A	$4.99 million	N/A
6/16/2026	Q4 2026	SNOA Sonoma Pharmaceuticals	-$0.24	-$0.33	-$0.09	-$0.33	$5.57 million	$5.56 million
5/6/2026	Q3 2026	INM InMed Pharmaceuticals	-$94.4436	-$0.69	+$93.7536	-$0.73	$1.20 million	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
INM InMed Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
LIAN LianBio	N/A	N/A	N/A	N/A	N/A
QLGN Qualigen Therapeutics	N/A	N/A	N/A	N/A	N/A
SNOA Sonoma Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
INM InMed Pharmaceuticals	N/A	3.12	3.12
LIAN LianBio	N/A	10.06	10.06
QLGN Qualigen Therapeutics	N/A	0.71	0.71
SNOA Sonoma Pharmaceuticals	N/A	2.50	1.75

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
INM InMed Pharmaceuticals	20.12%
LIAN LianBio	74.85%
QLGN Qualigen Therapeutics	3.18%
SNOA Sonoma Pharmaceuticals	1.95%

Insider Ownership

Company	Insider Ownership
INM InMed Pharmaceuticals	0.85%
LIAN LianBio	7.59%
QLGN Qualigen Therapeutics	1.80%
SNOA Sonoma Pharmaceuticals	2.29%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
INM InMed Pharmaceuticals	10	3.31 million	3.29 million	Not Optionable
LIAN LianBio	110	108.06 million	99.86 million	Not Optionable
QLGN Qualigen Therapeutics	50	1.70 million	1.66 million	Not Optionable
SNOA Sonoma Pharmaceuticals	180	4.79 million	4.68 million	Not Optionable

QLGN, INM, SNOA, and LIAN Headlines

Recent News About These Companies

Sonoma Pharmaceuticals Receives FDA 510(k) Clearance Expanding Indications and Packaging Options for Microdacyn(R) Wound Irrigation Solution

June 30, 2026 | accessnewswire.comA

Sonoma Pharmaceuticals Expands At-the-Market Equity Offering Capacity

June 18, 2026 | tipranks.com

Sonoma Pharmaceuticals, Inc.: Sonoma Pharmaceuticals Reports Fiscal Year and Fourth Quarter 2026 Financial Results

June 16, 2026 | finanznachrichten.de

Sonoma Pharmaceuticals Reports Fiscal Year and Fourth Quarter 2026 Financial Results

June 16, 2026 | accessnewswire.comA

What's going on with Sonoma Pharma stock Monday?

April 27, 2026 | msn.com

Sonoma Pharmaceuticals Announces Pricing of $4 Million Public Offering

April 25, 2026 | finance.yahoo.com

Sonoma Pharmaceuticals, Inc.: Sonoma Pharmaceuticals Announces U.S. Retail Launch of Advanced Burn Relief Hydrogel in CVS and Walmart

March 24, 2026 | finanznachrichten.de

Sonoma Pharmaceuticals Announces U.S. Retail Launch of Advanced Burn Relief Hydrogel in CVS and Walmart

March 24, 2026 | accessnewswire.comA

Sonoma Pharmaceuticals Announces Launch of New Dermatology Product Line under Person & Covey’s Aquanil Brand for Sensitive Skin

March 18, 2026 | freep.comF

Sonoma Pharmaceuticals Announces Launch of New Dermatology Product Line under Person & Covey's Aquanil Brand for Sensitive Skin

March 18, 2026 | accessnewswire.comA

Sonoma Pharmaceuticals, Inc.: Sonoma Pharmaceuticals Reports Third Fiscal Quarter 2026 Financial Results

February 10, 2026 | finanznachrichten.de

Sonoma Pharmaceuticals Reports Third Fiscal Quarter 2026 Financial Results

February 10, 2026 | accessnewswire.comA

Sonoma Pharmaceuticals, Inc.: Sonoma Pharmaceuticals Welcomes New Member of its Board of Directors and New Senior Vice President of Regulatory, Quality and Product Development

January 29, 2026 | finanznachrichten.de

Sonoma Pharmaceuticals Welcomes New Member of its Board of Directors and New Senior Vice President of Regulatory, Quality and Product Development

January 28, 2026 | accessnewswire.comA

Sonoma Pharmaceuticals, Inc.: National Rosacea Society Awards Seal of Acceptance to Sonoma Pharmaceuticals for Reliefacyn Advanced

November 14, 2025 | finanznachrichten.de

Sonoma Pharmaceuticals’ Reliefacyn Advanced receives NRS Seal of Acceptance

November 13, 2025 | msn.com

National Rosacea Society Awards Seal of Acceptance to Sonoma Pharmaceuticals for Reliefacyn Advanced

November 13, 2025 | accessnewswire.comA

Sonoma Pharmaceuticals reports higher revenue

November 7, 2025 | bizwest.comB

Sonoma Pharmaceuticals to Exhibit at MEDICA 2025 in Düsseldorf

November 6, 2025 | accessnewswire.comA

Sonoma Pharmaceuticals reports Q2 EPS (32c) vs. (59c) last year

November 4, 2025 | msn.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

QLGN, INM, SNOA, and LIAN Company Descriptions

InMed Pharmaceuticals NASDAQ:INM

$1.47 -0.03 (-2.00%)

Closing price 07/31/2026 04:00 PM Eastern

Extended Trading

$1.51 +0.04 (+2.72%)

As of 07/31/2026 07:21 PM Eastern

InMed Pharmaceuticals Inc., a clinical stage pharmaceutical company, develops a pipeline of prescription-based products. The company operates through two segments, the InMed and the BayMedica. The InMed segment researches and develops cannabinoid-based pharmaceuticals products. The BayMedica segment develops proprietary manufacturing technologies to produce and sell rare cannabinoids for the health and wellness industry. Its prescription-based products include rare cannabinoids and novel cannabinoid analogs for the treatment of diseases with high unmet medical needs. The company's lead product is INM-755, a cannabinol topical skin cream, completed Phase 2 clinical trial for the treatment of epidermolysis bullosa. It also develops INM-088, which is in preclinical studies for the treatment of glaucoma; and INM-900 for neurodegenerative diseases. In addition, the company offers IntegraSyn, an integrated biosynthesis-based manufacturing approach, for pharmaceutical-grade cannabinoids; and cannabichromene, cannabicitran, cannabidivarin, and tetrahydrocannabivarin. The company was formerly known as Cannabis Technologies Inc. and changed its name to InMed Pharmaceuticals Inc. in October 2014. InMed Pharmaceuticals Inc. was incorporated in 1981 and is headquartered in Vancouver, Canada.

LianBio NASDAQ:LIAN

$0.05 -0.01 (-16.64%)

As of 07/31/2026

LianBio, a biopharmaceutical company, engages in developing and commercializing medicines for cardiovascular, oncology, opthalmology, and inflammatory diseases in China and other Asian countries. The company develops mavacamten for the treatment of obstructive and non-obstructive hypertrophic cardiomyopathy, and heart failure with preserved ejection fraction; TP-03 for the treatment of Demodex blepharitis and meibomian gland disease; NBTXR3 for the treatment of head and neck squamous cell carcinoma, and solid tumor; Infigratinib for the treatment of second-line and first-line cholangiocarcinoma, and gastric cancers; BBP-398 for solid tumors; Omilancor and NX-13 for ulcerative colitis and Crohn's disease; LYR-210 for chronic rhinosinusitis; and Sisunatovir for respiratory syncytical virus. It has a partnership with Tarsus Pharmaceuticals, Inc. to develop and commercialize TP-03 for the treatment of Demodex blepharitis; and Nanobiotix S.A. to develop and commercialize NBTXR3, a radioenhancer designed to be injected directly into a malignant tumor prior to standard radiotherapy. The company was incorporated in 2019 and is headquartered in Princeton, New Jersey.

Qualigen Therapeutics NASDAQ:QLGN

$0.66 -0.01 (-1.25%)

As of 07/31/2026

Qualigen Therapeutics, Inc., a biotechnology company, focuses on the development and commercialization of novel therapeutic products for the treatment of cancer and infectious diseases. It offers FastPack, a patent-protected rapid, onsite immunoassay testing system. The company is developing QN-302 for the treatment of pancreatic ductal adenocarcinoma; QN-247, an oligonucleotide-based drug candidate to treat various nucleolin-expressing cancers, including liquid and solid tumors; QN-165, a drug candidate for the potential broad-spectrum treatment of infectious diseases, such as COVID-19; RAS-F, a small-molecule RAS oncogene protein-protein inhibitor that blocks RAS mutations and inhibits tumor formation; and selective target antigen removal system, a therapeutic device to remove circulating tumor cells, viruses, inflammation factors, and immune checkpoints. Qualigen Therapeutics, Inc. was founded in 1996 and is based in Carlsbad, California.

Sonoma Pharmaceuticals NASDAQ:SNOA

$1.10 -0.03 (-2.65%)

Closing price 07/31/2026 04:00 PM Eastern

Extended Trading

$1.14 +0.04 (+3.82%)

As of 07/31/2026 07:56 PM Eastern

Sonoma Pharmaceuticals, Inc., develops and produces stabilized hypochlorous acid (HOCl) products for wound care, animal health care, eye care, oral care, and dermatological conditions in the United States, Latin America, Europe, Asia, and internationally. The company offers Regenacyn, a prescription scar gel; Pediacyn, a pediatric dermatology and wound care product for over-the-counter (OTC) use; Epicyn, an Antimicrobial Facial Cleanser; Levicyn, an HOCl based prescription and OTC product to use and relieve skin irritations, lacerations, abrasions, and burns; Celacyn, a scar management gel; and SebuDerm to manage and relieve the burning, itching, erythema, scaling, and pain associated with seborrhea and seborrheic dermatitis. It also provides Gramaderm for the treatment of topical mild to moderate acne; Microcyn, a HOCl-based topical line of products designed to stimulate expedited healing by targeting a wide range of pathogens; Ocucyn eyelid and eyelash cleanser; Microdacyn60 oral care solution for the treatment of mouth and throat infections; and Podiacyn, a foot care product. In addition, the company offers MicrocynAH, an HOCl-based solution designed to relieve common symptoms of hot spots, scratches, skin rashes post-surgical sites, and irritated animal skin for healing; MicrocynVS, a veterinarian-strength animal care product used in vet clinics and animal hospitals; Nanocyn, a hospital-grade disinfectant; Acuicyn, an antimicrobial prescription solution for the treatment of blepharitis and the daily hygiene of eyelids and lashes; MucoClyns for the use in emergencies and safe to use on mucous membranes, cuts, abrasions, burns, and body surfaces; Endocyn root canal irrigation solutions; and Sinudox for nasal irrigation. The company was formerly known as Oculus Innovative Sciences, Inc. and changed its name to Sonoma Pharmaceuticals, Inc. in December 2016. Sonoma Pharmaceuticals, Inc. was incorporated in 1999 and is based in Boulder, Colorado.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest QLGN, INM, SNOA, and LIAN Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest QLGN, INM, SNOA, and LIAN Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

QLGN, INM, SNOA, and LIAN Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

QLGN, INM, SNOA, and LIAN Company Descriptions

InMed Pharmaceuticals NASDAQ:INM

LianBio NASDAQ:LIAN

Qualigen Therapeutics NASDAQ:QLGN

Sonoma Pharmaceuticals NASDAQ:SNOA

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest QLGN, INM, SNOA, and LIAN Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest QLGN, INM, SNOA, and LIAN Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

QLGN, INM, SNOA, and LIAN Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

QLGN, INM, SNOA, and LIAN Company Descriptions

InMed Pharmaceuticals NASDAQ:INM

LianBio NASDAQ:LIAN

Qualigen Therapeutics NASDAQ:QLGN

Sonoma Pharmaceuticals NASDAQ:SNOA

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools